No Data
No Data
Kingchem: Half-year report for the year 2024.
Kingchem: Summary of Half-Year Report in 2024.
JinkaiShengke (301509.SZ) released its performance for the first half of the year, with a net income of 32.0917 million yuan, a decrease of 71.32%.
Jinkai Biosciences (301509.SZ) released its 2024 interim report, with a revenue of 0.262 billion...
Jinkai Biological (301509.SZ): The net income for the first half of the year was 32.0917 million yuan, a 71.32% year-on-year decrease.
Jinkai Life Sciences (301509.SZ) announced its semi-annual report for 2024, with revenue of 0.262 billion yuan, a decrease of 39.36% year-on-year; net income attributable to shareholders of the listed company was 32.0917 million yuan, a decrease of 71.32% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 24.505 million yuan, a decrease of 78.03% year-on-year; basic earnings per share was 0.27 yuan.
As of August 9, 2024, the total number of shareholders for Jinkai Bioscience (301509.SZ) was 14,631.
On August 13th, Gelunhui reported that as of August 9th, 2024, the total number of shareholders in the company was 14,631.
Jinkai Life Sciences (301509.SZ) does not involve the provision of vitamin products and services in its business.
Jinkai Life Science (301509.SZ) stated on its investor platform on August 13 that its business does not involve vitamin product services.
No Data